Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Allergy Immunotherapy Market

ID: MRFR/HC/54526-HCR
200 Pages
Nidhi Mandole
Last Updated: May 12, 2026

UK Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) and By Patient Type (Pediatric, Adult, Geriatric) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Allergy Immunotherapy Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 UK Allergy Immunotherapy Market, BY Indication (USD Million) | |
      1. 4.1.1 Allergic Rhinitis | |
      2. 4.1.2 Allergic Asthma | |
      3. 4.1.3 Atopic Dermatitis | |
      4. 4.1.4 Food Allergies |
    2. 4.2 UK Allergy Immunotherapy Market, BY Type of Immunotherapy (USD Million) | |
      1. 4.2.1 Subcutaneous Immunotherapy | |
      2. 4.2.2 Sublingual Immunotherapy | |
      3. 4.2.3 Oral Immunotherapy | |
      4. 4.2.4 Intranasal Immunotherapy |
    3. 4.3 UK Allergy Immunotherapy Market, BY Administration Route (USD Million) | |
      1. 4.3.1 Injection | |
      2. 4.3.2 Sublingual | |
      3. 4.3.3 Oral | |
      4. 4.3.4 Intranasal |
    4. 4.4 UK Allergy Immunotherapy Market, BY Patient Age Group (USD Million) | |
      1. 4.4.1 Pediatric | |
      2. 4.4.2 Adult | |
      3. 4.4.3 Geriatric | |
      4. 4.4.4 Adolescent 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the UK Allergy Immunotherapy Market | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the UK Allergy Immunotherapy Market | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Allergopharma (DE) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 ALK-Abello (DK) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Merck KGaA (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Stallergenes Greer (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Aimmune Therapeutics (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Boehringer Ingelheim (DE) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Sanofi (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Bayer (DE) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 UK MARKET ANALYSIS BY INDICATION |
    6. 6.3 UK MARKET ANALYSIS BY TYPE OF IMMUNOTHERAPY |
    7. 6.4 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    8. 6.5 UK MARKET ANALYSIS BY PATIENT AGE GROUP |
    9. 6.6 KEY BUYING CRITERIA OF UK ALLERGY IMMUNOTHERAPY MARKET |
    10. 6.7 RESEARCH PROCESS OF MRFR |
    11. 6.8 DRO ANALYSIS OF UK ALLERGY IMMUNOTHERAPY MARKET |
    12. 6.9 DRIVERS IMPACT ANALYSIS: UK ALLERGY IMMUNOTHERAPY MARKET |
    13. 6.10 RESTRAINTS IMPACT ANALYSIS: UK ALLERGY IMMUNOTHERAPY MARKET |
    14. 6.11 SUPPLY / VALUE CHAIN: UK ALLERGY IMMUNOTHERAPY MARKET |
    15. 6.12 UK ALLERGY IMMUNOTHERAPY MARKET, BY INDICATION, 2024 (% SHARE) |
    16. 6.13 UK ALLERGY IMMUNOTHERAPY MARKET, BY INDICATION, 2024 TO 2035 (USD Million) |
    17. 6.14 UK ALLERGY IMMUNOTHERAPY MARKET, BY TYPE OF IMMUNOTHERAPY, 2024 (% SHARE) |
    18. 6.15 UK ALLERGY IMMUNOTHERAPY MARKET, BY TYPE OF IMMUNOTHERAPY, 2024 TO 2035 (USD Million) |
    19. 6.16 UK ALLERGY IMMUNOTHERAPY MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
    20. 6.17 UK ALLERGY IMMUNOTHERAPY MARKET, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million) |
    21. 6.18 UK ALLERGY IMMUNOTHERAPY MARKET, BY PATIENT AGE GROUP, 2024 (% SHARE) |
    22. 6.19 UK ALLERGY IMMUNOTHERAPY MARKET, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million) |
    23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    24. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    25. 7.2 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY INDICATION, 2026-2035 (USD Million) | |
      2. 7.2.2 BY TYPE OF IMMUNOTHERAPY, 2026-2035 (USD Million) | |
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2026-2035 (USD Million) | |
      4. 7.2.4 BY PATIENT AGE GROUP, 2026-2035 (USD Million) |
    26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    27. 7.4 ACQUISITION/PARTNERSHIP | |

UK Allergy Immunotherapy Market Segmentation

UK Allergy Immunotherapy Market By Indication (USD Million, 2022-2035)

  • Allergic Rhinitis
  • Allergic Asthma
  • Atopic Dermatitis
  • Food Allergies

UK Allergy Immunotherapy Market By Type of Immunotherapy (USD Million, 2022-2035)

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
  • Oral Immunotherapy
  • Intranasal Immunotherapy

UK Allergy Immunotherapy Market By Administration Route (USD Million, 2022-2035)

  • Injection
  • Sublingual
  • Oral
  • Intranasal

UK Allergy Immunotherapy Market By Patient Age Group (USD Million, 2022-2035)

  • Pediatric
  • Adult
  • Geriatric
  • Adolescent

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions